孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜疗效观察  

Therapeutic effect of montelukast sodium combined with loratadine on children with Henoch Schonlein purpura

作　　者：宋艳 张炜灵[1] 杜丽琴 SONG Yan;ZHANG Wei-ling;DU Li-qin(Department of Pediatrics,Shenzhen Bao'an District People's Hospital,Shenzhen 518100,Guangdong,CHINA)

机构地区：[1]深圳市宝安区人民医院儿科,广东深圳518100

出　　处：《海南医学》2020年第16期2096-2098,共3页Hainan Medical Journal

摘　　要：目的观察孟鲁司特钠联合氯雷他定治疗过敏性紫癜患儿的临床疗效,并探讨其对患儿血清白细胞介素-2(IL-2)和白细胞介素-6(IL-6)水平的影响。方法选择2018年8月至2020年1月期间深圳市宝安区人民医院儿科收治的94例过敏性紫癜患儿为研究对象,按随机数表法将患儿分为A组(n=31)、B组(n=30)、C组(n=33),分别接受氯雷他定、孟鲁司特钠以及氯雷他定+孟鲁司特钠治疗,总疗程为4周。比较三组患儿治疗前及治疗后的血清IL-2、IL-6水平;记录患儿临床症状消失时间,疗程结束后评价临床疗效。结果三组患儿治疗后,血清IL-2水平上升,IL-6水平降低,且C组IL-2、IL-6水平分别为(20.87±3.28)pg/mL、(10.54±2.52)pg/mL,明显优于A组的(12.64±2.48)pg/mL、(16.48±3.29)pg/mL和B组的(14.38±2.01)pg/mL、(15.28±3.82)pg/mL,差异均有统计学意义(P<0.05);C组患儿的皮疹、消化道症状及关节痛消失时间分别为(5.15±1.24)d、(3.22±0.84)d、(3.32±1.08)d,均明显短于A组的(8.23±2.09)d、(6.31±1.30)d、(7.42±1.97)d和B组的(7.95±2.13)d、(5.54±1.63)d、(6.93±2.53)d,差异均有统计学意义(P<0.05);C组患儿治疗总有效率为93.94%,明显高于A组的77.42%和B组的80.00%,差异有统计学意义(P<0.05)。结论孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜可以有效调节炎症因子水平,缩短病程,进而提高临床疗效。Objective To investigate the clinical efficacy of montelukast sodium combined with loratadine in the treatment of Henoch Schonlein purpura,and the effect of on the serum levels of IL-2 and IL-6.Methods A total of 94 children with Henoch Schonlein purpura,who admitted to Department of Pediatrics,Shenzhen Bao'an District People's Hospital from August 2018 to January 2020 were selected and divided into group A(n=31),group B(n=30)and group C(n=33)according to random number table method.They were respectively treated with loratadine,montelukast sodium and loratadine+montelukast sodium for 4 weeks.The serum levels of IL-2 and IL-6 were compared before and after treatment.The disappearance time of the clinical symptoms was recorded and the clinical effect was evaluated after treatment.Results After treatment,the serum level of IL-2 increased and the serum level of IL-6 significantly decreased,the serum levels of IL-2 and IL-6 in group C were(20.87±3.28)pg/mL,(10.54±2.52)pg/mL,which were significantly lower than corresponding(12.64±2.48)pg/mL,(16.48±3.29)pg/mL in group A and corresponding(14.38±2.01)pg/mL,(15.28±3.82)pg/mL in group B(all P<0.05).The disappearance time of arthralgia was(5.15±1.24)d,(3.22±0.84)d,(3.32±1.08)d,respectively,which were significantly shorter than corresponding(8.23±2.09)d,(6.31±1.30)d,(7.42±1.97)d of group A and corresponding(7.95±2.13)d,(5.54±1.63)d,(6.93±2.53)d of group B(all P<0.05).The total effective rate of group C was 93.94%,which was significantly higher than 77.42%of group A and 80.00%group B(P<0.05).Conclusion In treatment of Henoch Schonlein purpura,montelukast sodium combined with loratadine can effectively regulate the level of inflammatory factors,shorten the course of disease,and improve the clinical efficacy.

关 键 词：儿童 过敏性紫癜 孟鲁司特钠 氯雷他定 炎症因子 疗效 

分 类 号：R729[医药卫生—儿科]